Ipamorelin Research Overview (also known as NNC-26-0161, Ipamorelin pentapeptide, Aib-His-D-2Nal-D-Phe-Lys-NH2)
A selective, third-generation GHRP studied for its mild but consistent GH-releasing effects without significant impact on cortisol, prolactin, or appetite. Frequently combined with CJC-1295 No-DAC for pulsatile GH support. Studied for recovery, fat metabolism, sleep quality, and joint support.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide and selective GH secretagogue — a ghrelin/GHSR-1a receptor agonist engineered for selectivity that produces clean, physiological GH pulses without the side effects of cortisol, prolactin, or acetylcholine elevation that limit earlier GHRPs. It is widely considered the most selective and well-tolerated member of the GHRP family for chronic research administration.
Selectivity Advantage
Earlier GHRPs produce side effects through off-target receptor activation: GHRP-6 produces pronounced hunger stimulation; GHRP-2 elevates cortisol and prolactin; Hexarelin produces the most robust GH pulse but fastest receptor desensitization. Ipamorelin was specifically engineered to avoid these off-target effects — producing GH pulses with minimal cortisol, prolactin, or appetite effects, even at doses producing maximal GH release.
Research Applications
Ipamorelin produces GH pulses that closely mimic natural physiology — a sharp rise to peak within 15 minutes, returning toward baseline within 2–3 hours. It is frequently combined with GHRH analogs (CJC-1295 no DAC, Sermorelin) for synergistic GH release. Research applications include GH restoration protocols, body composition optimization, recovery from injury and surgery, sleep quality improvement, and anti-aging applications.
Quick Reference
| Literature-Reported Dose Range | 100–300 mcg per injection |
| Literature-Reported Frequency | 1-3x daily |
| Literature-Reported Cycle Length | 3-6 months |
| Literature-Reported Washout | 1-2 months |
| Storage | Refrigerate, use within 28 days |
| Sites Reported in Studies | Belly, thigh, upper arm |
| Timing | Empty stomach, bedtime optimal for sleep |
Research Indications
Growth Hormone
Natural GH Stimulation
Stimulates pituitary gland to release growth hormone naturally with consistent elevation 30-60 minutes post-injection, maintaining healthy pulsatile patterns.
IGF-1 Enhancement
Increases insulin-like growth factor-1 production through natural GH pathways, mediating growth hormone's beneficial effects on muscle, bone, and tissue.
Anti-Aging Benefits
Supports cellular regeneration, collagen synthesis, and metabolic function through enhanced growth hormone pathways without disrupting natural hormone balance.
Body Composition
Lean Muscle Development
Promotes muscle protein synthesis and nitrogen retention when combined with resistance training, leading to increased lean mass over 12-16 weeks.
Fat Loss Support
Enhances lipolysis and metabolic rate through GH-mediated pathways, improving overall body composition and reducing visceral fat accumulation.
Body Recomposition
Improves overall body composition with simultaneous increase in lean mass and reduction in fat mass, particularly effective for aging populations.
Recovery
Sleep Enhancement
Increases slow-wave sleep duration and quality when taken before bed, leading to more restorative sleep and improved morning energy levels.
Exercise Recovery
Accelerates recovery from exercise-induced muscle damage with reduced soreness, faster performance restoration, and enhanced training adaptations.
Tissue Repair
Supports tissue repair and cellular regeneration during sleep through enhanced growth hormone release and improved recovery processes.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General Health & Longevity | 200mcg | 1x daily before bed | SubQ |
| Body Composition | 250-300mcg | 2x daily (morning, pre-workout) | SubQ |
| Athletic Performance | 200-250mcg | 2-3x daily | SubQ |
| Sleep & Recovery | 200mcg | 1x daily 30min before bed | SubQ |
| Anti-Aging Protocol | 200-250mcg | 1-2x daily | SubQ |
Timing
Recommended administration window: empty stomach, bedtime optimal for sleep. Typical onset: 2-4 weeks for sleep, 6-8 weeks for body composition.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
Gold standard combination - CJC extends GH release while Ipamorelin provides the pulse for optimal growth hormone cycles
BPC-157 upregulates GH receptors, potentially enhancing Ipamorelin effectiveness for recovery and muscle growth
Redundant GH stimulation pathways, may cause receptor desensitization
Similar mechanism with higher hunger effects, stick to Ipamorelin for cleaner profile
Ipamorelin is a GHRP (growth hormone releasing peptide) and pairs well with ONE GHRH analog. Do not combine Sermorelin with another GHRH analog (CJC-1295 or Tesamorelin) in the same protocol — this causes GHRH receptor competition and redundancy. Choose one GHRH analog to pair with Ipamorelin.
Combining two GHRPs offers minimal additive GH benefit over using one alone, as they compete at the same ghrelin/GHS-R1a receptor. Not generally recommended — choose the GHRP best suited to your goals (Ipamorelin for clean GH pulses; Hexarelin/GHRP-6 if cardioprotection or appetite stimulation is a priority).
Reported Research Timeline
01Week 1–2 (reported in cited studies): improved sleep quality, deeper sleep, better morning energy
02Week 2–4 (reported in cited studies): enhanced recovery from exercise, reduced muscle soreness
03Week 4–8 (reported in cited studies): body composition improvements, increased lean mass, fat loss
04Week 8–12 (reported in cited studies): continued improvements in muscle tone, skin quality, energy
05Most effective for: Sleep optimization, body recomposition, anti-aging
Side effects (reported in cited studies): minimal, occasional mild hunger increase
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
May cause mild hunger increase 20-30 minutes post-injection
Monitor for receptor desensitization after 3-4 months of continuous use
Cycle off periodically to maintain effectiveness and receptor sensitivity
Not recommended during pregnancy, breastfeeding, or active cancer
Use sterile injection technique to prevent infection
Seek Medical Attention If:
Loss of effectiveness after 3-4 months (time to cycle off)
Persistent injection site reactions or unusual swelling
Excessive fatigue, unusual hunger, or sleep disturbances
Any concerning symptoms or unexpected reactions
Always consult your healthcare provider with questions
Quality Indicators
Verified Marker
White, Fine Crystalline Powder
Quality Ipamorelin appears as white, fine crystalline powder with no clumping or discoloration.
Verified Marker
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Verified Marker
Mild Hunger Response
Quality Ipamorelin should produce mild hunger increase 20-30 minutes after injection, indicating proper ghrelin receptor activation.
Acceptable Range
Slight Drowsiness (Bedtime Use)
When taken before bed, may cause mild drowsiness as growth hormone release promotes natural sleep onset.
Quality Concern
Yellow or Discolored Powder
Any discoloration suggests degradation or contamination. Quality Ipamorelin should be pure white.
Quality Concern
No Physiological Response
Lack of hunger response, sleep improvement, or effects after 1-2 weeks may indicate inactive or degraded peptide.
Research Citations
- Safety and Tolerability Analysis (2023)
Multi-center study | Various doses | Long-term safety assessment - Athletic Performance Study (2022)
Athletes | 200-300mcg daily | Performance and recovery markers - Sleep Quality Research (2021)
Adults with sleep issues | 200mcg before bed | 6-week study - Body Composition Clinical Trial (2020)
Adults 45+ | 250mcg daily | 12-week study | Lean mass and bone density - Growth Hormone Stimulation Study (2019)
Adults | 200mcg daily | 8-week study | Consistent GH elevation - Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, 2026, Am J Sports Med - Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Johansen PB, Nowak J, Skjaerbaek C, 1999, Growth Horm IGF Res - The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
Svensson J, Lall S, Dickson SL, 2000, J Endocrinol - Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L, 2026, Int J Mol Sci - Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats
Aagaard NK, Grøfte T, Greisen J, 2009, Growth Horm IGF Res
Research Focus
Growth hormone release, Clean GH pulse, Body composition, Recovery, Anti-aging, Selective GHS-R agonism
Verified Vendors Carrying Ipamorelin
Frequently Asked Questions
What should researchers watch for with Ipamorelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Ipamorelin?
Week 1–2 (reported in cited studies): improved sleep quality, deeper sleep, better morning energy
How is Ipamorelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →